Intimidation, Politics and Drug Industry Cripple U.S. Medicine – FDA Permits Dr. David Graham to publish Vioxx Report Wed, 5 Jan 2005 FDA officials could not maintain their iron grip in an effort to suppress evidence of far reaching lethal effects of Vioxx when their actions were in full public…
Alliance for Human Research Protection in the Press Feb 17, 2005: FDA Critics Slam Plan for Safety Reform – Nature “This is smoke and mirrors and musical chairs,” says Vera Sharav, president of the New York-based Alliance for Human Research Protection. “They will be using the very same officials that…
Credibility Crisis:Survey FDA Scientists – Death in NIH-AIDS Trial – Tauzin Moves to PhRMA Thu, 16 Dec 2004 A credibility crisis in medical research is smoldering: like the Enron accounting scandal, the prescription-drug debacle is a matter of systemic corruption, including gross and widespread failure by the regulatory process. Unlike…
Infomail 2004 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 31: FDA to review “missing” drug company documents Dec 30: Family of Woman Killed by AIDS Drug Test Sues Doctors, Manufacturer Dec 30: Doctors, Too, Ask: Is This Drug Right? Dec 29: Bill would shield…
Forbes: Face of The Year: David Graham Mon, 13 Dec 2004 Â Forbes magazine has named Dr. David Graham the Face of the Year’ for his “steadfast advocacy of drug safety and his willingness to blow the whistle on his bosses.” Dr. Graham took a courageous stand as a responsible…
Grassley Calls for Safety Review /Unsafe Drugs Marketed to Consumers / FDA Lacks Leadership Sun, 19 Dec 2004 “We expect the FDA to not put a drug on the market that’s not safe. And you can’t compromise safety, regardless of how much pressure there is to get more drugs on…
Columbia Journalism Review–The Complicity of the Media in Drug Marketing Wed, 27 Jul 2005 An excellent article in the Columbia Journalism Review examines pharmaceutical industry hype and the media’s role in helping that industry create false impressions about the safety and benefits of newly marketed drugs: “stories trumpeting new drugs…
A Special Article By Curt D. Furberg, MD, PhD; Arthur A. Levin, MPH; Peter A. Gross, MD; Robyn S. Shapiro, JD; Brian L. Strom, MD, MPH
The FDA appears to have learned nothing from recent catastrophic disasters.
Good news! The Associated Press reports that the U.S. Merit Systems Proteciton Board ruled in favor of extending whistleblower protection to ALL government doctors, including those hired under Title 42.
"This is out-of-control use of drugs that have profound cardiovascular consequences. We have got a potential public health crisis. I think patients and families need to be made aware of these concerns."
October 14, 2005 link to pdf of original letter Dr. Russell Katz Director, Neuropharmacological Drug Products Food and Drug Administration, FDA 120 1451 Rockville Pike, Room 4037 Rockville, MD 20852 Re: FDA Neurontin Safety Analyses Dear Dr. Katz: Due to the continued public danger facing a substantial class of…
